A 16-year-old girl had melanoma with the BRAF V600E mutation that metastasized to the brain. The response to vemurafenib was dramatic, and the patient continues to improve 6 months after starting therapy.
No takes yet. Share an insight, caveat, or question.
Rochet et al. (2011) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: